Market Cap: $84.84M
RC
Rallybio Corporation
RLYB
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $84.84M
Rallybio Advances Innovative Therapies for Rare Diseases Rallybio Corporation, a clinical-stage biotechnology firm dedicated to developing treatments for rare diseases, highlights its significant achi…
Rallybio Sets Ambitious Goals in Rare Disease Therapies for 2025 Rallybio Corporation, a clinical-stage biotechnology firm specializing in therapies for rare diseases, showcases its commitment to inno…
Rallybio Advances Research on Rare Disease Therapies at ASH Annual Meeting Rallybio Corporation, a clinical-stage biotechnology firm specializing in treatments for rare diseases, makes a significant i…
Rallybio Showcases Innovative Therapies at ASH Annual Meeting Rallybio Corporation, a clinical-stage biotechnology company dedicated to developing therapies for rare diseases, highlights significant a…
Innovative Approaches in Drug Development for Pregnant Women: Rallybio's TMDD Model Rallybio Corporation, a clinical-stage biotechnology company focused on therapies for rare diseases, makes strides i…
Rallybio Advances Commitment to Rare Disease Therapies Rallybio Corporation, a clinical-stage biotechnology firm based in New Haven, Connecticut, is making significant strides in developing transforma…
Rallybio Advances Rare Disease Therapies Amid Upcoming Conference Participation Rallybio Corporation, a clinical-stage biotechnology company based in New Haven, Connecticut, remains focused on develop…